Hunterbrook Capital on Tuesday revealed it is long on Achieve Life Sciences (ACHV) stock as the company nears a green light from the US Food and Drug Administration for cytisinicline as a treatment for smoking addiction. The FDA is expected to rule on its application seeking approval for the drug by June 20, 2026.